KODIAK SCIENCES INC. Proceeds from Notes Payable
KODIAK SCIENCES INC. (KOD) reported Proceeds from Notes Payable of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2021-03-01
- KODIAK SCIENCES INC. proceeds from notes payable for the quarter ending 2018-12-31 was $0.00.
- KODIAK SCIENCES INC. proceeds from notes payable for the quarter ending 2018-09-30 was $0.00.
- KODIAK SCIENCES INC. proceeds from notes payable for the quarter ending 2018-06-30 was $0.00.
- KODIAK SCIENCES INC. proceeds from notes payable for the quarter ending 2018-03-31 was $33.00M.
- KODIAK SCIENCES INC. proceeds from notes payable for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- KODIAK SCIENCES INC. proceeds from notes payable for fiscal 2018 was $33.00M, a 230.00% increase from fiscal 2017.
- KODIAK SCIENCES INC. proceeds from notes payable for fiscal 2017 was $10.00M.
- KODIAK SCIENCES INC. proceeds from notes payable for fiscal 2016 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-16 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $33.00M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $0.00 derived: sum of 2 quarters · filed 2019-11-12 | $33.00M 10-Q · filed 2019-11-12 | $33.00M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $33.00M 10-Q · filed 2019-08-14 | $33.00M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2018-03-31 | $33.00M 10-Q · filed 2019-05-15 | $33.00M derived: sum of 2 quarters · filed 2020-03-16 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $10.00M 10-K · filed 2020-03-16 | ||
| 2017-09-30 | $10.00M 10-Q · filed 2018-11-16 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |